Ligand Pharmac-B

Forecast & Rating12 analysts currently cover Ligand Pharmac-B, with about 91.7% giving a positive rating — meaning they expect the stock to rise. The average price target is $344.25, about 14.1% upside from the current price of $301.81. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 51.4% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Ligand Pharmac-B closely still see room for the stock to rise. Data as of Sep 25, 2026; for reference only and not investment advice.